These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 18537616)

  • 1. Progress in the development of matrix metalloproteinase inhibitors.
    Tu G; Xu W; Huang H; Li S
    Curr Med Chem; 2008; 15(14):1388-95. PubMed ID: 18537616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinase inhibitors.
    Ramnath N; Creaven PJ
    Curr Oncol Rep; 2004 Mar; 6(2):96-102. PubMed ID: 14751086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent developments in patent anti-cancer agents targeting the matrix metalloproteinases (MMPs).
    Li X; Wu JF
    Recent Pat Anticancer Drug Discov; 2010 Jun; 5(2):109-41. PubMed ID: 19951249
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors.
    Skiles JW; Gonnella NC; Jeng AY
    Curr Med Chem; 2004 Nov; 11(22):2911-77. PubMed ID: 15544483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors.
    Skiles JW; Gonnella NC; Jeng AY
    Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances in the development of MMPIs and APNIs based on the pyrrolidine platforms.
    Li X; Li J
    Mini Rev Med Chem; 2010 Aug; 10(9):794-805. PubMed ID: 20482497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment.
    Zucker S; Cao J; Chen WT
    Oncogene; 2000 Dec; 19(56):6642-50. PubMed ID: 11426650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility.
    Dormán G; Cseh S; Hajdú I; Barna L; Kónya D; Kupai K; Kovács L; Ferdinandy P
    Drugs; 2010 May; 70(8):949-64. PubMed ID: 20481653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase inhibitors (MMPIs) as attractive therapeutic targets: Recent progress and current challenges.
    Shi Y; Ma X; Fang G; Tian X; Ge C
    NanoImpact; 2021 Jan; 21():100293. PubMed ID: 35559782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase inhibitors for cancer therapy:the current situation and future prospects.
    Fingleton B
    Expert Opin Ther Targets; 2003 Jun; 7(3):385-97. PubMed ID: 12783574
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential clinical applications of matrix metalloproteinase inhibitors and their future prospects.
    Li W; Saji S; Sato F; Noda M; Toi M
    Int J Biol Markers; 2013 Jun; 28(2):117-30. PubMed ID: 23787494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydroxamic acids as matrix metalloproteinase inhibitors.
    Verma RP
    Exp Suppl; 2012; 103():137-76. PubMed ID: 22642192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.
    Piperigkou Z; Manou D; Karamanou K; Theocharis AD
    Methods Mol Biol; 2018; 1731():325-348. PubMed ID: 29318564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamic considerations in the use of matrix metalloproteinase inhibitors in cancer treatment.
    Yang JS; Lin CW; Su SC; Yang SF
    Expert Opin Drug Metab Toxicol; 2016; 12(2):191-200. PubMed ID: 26852787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting.
    Gialeli C; Theocharis AD; Karamanos NK
    FEBS J; 2011 Jan; 278(1):16-27. PubMed ID: 21087457
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase inhibitors: applications in oncology.
    Yip D; Ahmad A; Karapetis CS; Hawkins CA; Harper PG
    Invest New Drugs; 1999; 17(4):387-99. PubMed ID: 10759405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Matrix metalloproteinase enzymes and their naturally derived inhibitors: novel targets in photocarcinoma therapy.
    Gupta A; Kaur CD; Jangdey M; Saraf S
    Ageing Res Rev; 2014 Jan; 13():65-74. PubMed ID: 24355347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular Imaging Probes Based on Matrix Metalloproteinase Inhibitors (MMPIs).
    Rangasamy L; Geronimo BD; Ortín I; Coderch C; Zapico JM; Ramos A; de Pascual-Teresa B
    Molecules; 2019 Aug; 24(16):. PubMed ID: 31426440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies.
    Rao BG
    Curr Pharm Des; 2005; 11(3):295-322. PubMed ID: 15723627
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.